Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.990
+0.080 (1.63%)
At close: Jul 10, 2026, 4:00 PM EDT
4.990
0.00 (0.00%)
After-hours: Jul 10, 2026, 4:10 PM EDT
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
399.34M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 69.21M |
| vTv Therapeutics | 36.84M |
| Abeona Therapeutics | 14.54M |
| X4 Pharmaceuticals | 9.01M |
| Adlai Nortye | 5.00M |
| Upstream Bio | 3.32M |
AVIR News
- 15 days ago - Atea Pharmaceuticals completes patient enrollment in C-FORWARD trial - TheFly
- 15 days ago - Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - GlobeNewsWire
- 22 days ago - Atea Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - Atea Pharmaceuticals Slides: Q1 2026 - Filings
- 2 months ago - Atea Pharmaceuticals Earnings release: Q1 2026 - Filings